Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18360467 | 0.88 | LMNA (0.48) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL18360485 | 0.86 | CA1 (0.56) | SMN1; SMN2CA1CA2CA12CA9 | |
| SCHEMBL18360533 | 0.85 | LMNA (0.57) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL18360483 | 0.84 | CA1 (0.60) | SMN1; SMN2CA1CA2CA12CA9 | |
| SCHEMBL18360527 | 0.82 | CA1 (0.41) | CA1CA2CA12CA9 | |
| SCHEMBL18360450 | 0.80 | NPC1 (0.47) | SMN1; SMN2CA1CA2CA12CA9 | |
| SCHEMBL28429389 | 0.80 | CA1 (0.44) | CA1CA2CA12CA9 | |
| SCHEMBL18360487 | 0.77 | CA1 (0.42) | CA1CA2CA12CA9 | |
| SCHEMBL29529370 | 0.77 | CA1 (0.40) | CA1CA2CA12CA9 | |
| SCHEMBL18360523 | 0.77 | HPGD (0.48) | LMNACA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000133-A1 | BENZOXABOROLE FUNGICIDES | SYNGENTA PARTICIPATIONS AG (SE) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000133-A1 | BENZOXABOROLE FUNGICIDES | CYP4X1, BROX, CYP1B1 | LMNA 2058/4885SMN1; SMN2 2375/4885CA1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.